Fate Therapeutics (FATE) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Protalix BioTherapeutics (DE) (PLX) over the past year, gaining 54.7% versus a gain of 8.4%. Over five years, PLX leads with a +120.3% price change compared with -96.5% for FATE. Fate Therapeutics is the larger company by market cap ($257.6 million vs $218.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | PLX |
|---|---|---|
| Share price | $2.15 | $2.71 |
| Market cap | $257.61M | $218.35M |
| 1-day change | -6.11% | -0.73% |
| YTD return | +119.39% | +50.56% |
| 1-year return | +54.68% | +8.40% |
| 5-year return | -96.49% | +120.33% |
| P/E ratio (TTM) | — | 11.78 |
| Forward P/E | — | 4.37 |
| EPS (TTM) | $-1.05 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $3.19 |
| 52-week low | $0.95 | $1.60 |
| Distance from 52-week high | -33.44% | -15.05% |
| Analyst consensus | buy | none |
| Avg. price target upside | +166.98% | +305.90% |
| Average volume | 1.90M | 731.66K |
| Shares outstanding | 119.82M | 80.57M |
| Employees | 161 | 226 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed PLX by 46.3 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Healthcare · Biotechnology · 161 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Healthcare · Biotechnology · 226 employees
FATE vs PLX FAQ
Which is bigger, Fate Therapeutics or Protalix BioTherapeutics (DE)?
Fate Therapeutics (FATE) is larger, with a market capitalization of $257.61M compared with $218.35M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, FATE or PLX?
FATE returned +54.68% over the past 12 months, compared with +8.40% for PLX (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.